Global Landscape and Thematic Evolution of Selective GLP‐1 Receptor Agonists and GLP‐1–Based Multi‐Receptor Agonists in Type 2 Diabetes Mellitus: A Bibliometric Analysis
Yanbing Wang, Zhanru Liu, Shifeng Wang, Cuiyan Lv, Hesham R El‐Seedi, Shaden A M Khalifa, Haiyan Wang · 2026
Read Global Landscape and Thematic Evolution of Selective GLP‐1 Receptor Agonists and GLP‐1–Based Multi‐Receptor Agonists in Type 2 Diabetes Mellitus: A Bibliometric Analysis by Yanbing Wang, Zhanru Liu, Shifeng Wang, Cuiyan Lv, Hesham R El‐Seedi, Shaden A M Khalifa, Haiyan Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13627873.txt.
Description
Yanbing Wang and colleagues chart the world literature on GLP-1 medicines for type 2 diabetes, the gut-hormone drugs that have reshaped diabetes and weight care. Their bibliometric sweep of the Web of Science gathered 3,736 original articles from 2004 to 2025 and mapped who publishes, who partners with whom, and which themes rise and fall. Single-target GLP-1 studies still form the core pile, while head-to-head and multi-receptor studies have surged lately.
The United States leads in output and in international ties, and two drug makers, Novo Nordisk and Eli Lilly, stand out as the most present institutions. Landmark outcome trials and joint diabetes guidelines drew the heaviest citations. Topics have swung from basic hormone biology toward heart, kidney, and weight outcomes and real-world use, the field's center of gravity in one map.
Catalog record
| CREATOR | Yanbing Wang, Zhanru Liu, Shifeng Wang, Cuiyan Lv, Hesham R El‐Seedi, Shaden A M Khalifa, Haiyan Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |